Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound paclitaxel + fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Albumin-bound paclitaxel + fluorouracil + leucovorin is a combination chemotherapy regimen investigated for the treatment of advanced gastric cancer. The regimen utilizes nab-paclitaxel, a nanoparticle formulation of paclitaxel that avoids the need for solvents like Cremophor EL, potentially reducing hypersensitivity reactions and improving delivery to tumor tissues. This is combined with 5-fluorouracil (5-FU), a pyrimidine analog that acts as an antimetabolite by inhibiting thymidylate synthase, and leucovorin (calcium folinate), which acts as a biochemical modulator to enhance the binding of 5-FU to its target enzyme. This combination has been specifically studied as a second-line treatment option for patients with advanced gastric cancer who have not previously been treated with taxanes.
- Brand names
- Abraxane
- Other names
- nab-paclitaxel + 5-FU + CFnab-paclitaxel + 5-FU + leucovorinnab-paclitaxel + 5-FU + folinic acidAlbumin Bound Paclitaxel + 5-FU + CF
02
Targets
SPARC (Secreted protein acidic and rich in cysteine)TS (Thymidylate synthase)gp60 (GP60 Receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on albumin-bound paclitaxel + fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound paclitaxel + fluorouracil + leucovorin.